Home  »  Business   »  Is Moderna Inc. (NASDAQ: MRNA) A Good Investment N...

Is Moderna Inc. (NASDAQ: MRNA) A Good Investment Now?

Moderna Inc. (NASDAQ:MRNA) shares, rose in value on Friday, August 05, with the stock price down by -1.71% to the previous day’s close as strong demand from buyers drove the stock to $190.85.

Actively observing the price movement in the recent trading, the stock is buoying the session at $194.18, falling within a range of $185.47 and $197.44. The value of beta (5-year monthly) is 1.65 whereas the PE ratio is 5.71 over 12-month period. Referring to stock’s 52-week performance, its high was $497.49, and the low was $115.61. On the whole, MRNA has fluctuated by 21.70% over the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

With the market capitalization of Moderna Inc. currently standing at about $74.38 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $4.55, which is expected to increase to $13.09 for fiscal year $27.78 and then to about $8.66 by fiscal year 2023. Data indicates that the EPS growth is expected to be -1.80% in 2023, while the next year’s EPS growth is forecast to be -68.80%.

Analysts have estimated the company’s revenue for the quarter at $4.07 billion, with a low estimate of $2.54 billion and a high estimate of $4.7 billion. According to the average forecast, sales growth in current quarter could jump down -6.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $22.02 billion, representing an increase of 19.20% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MRNA’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MRNA currently trading nearly 13.52% and 26.38% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 68.66, while the 7-day volatility ratio is showing 5.84% which for the 30-day chart, stands at 5.72%. Furthermore, Moderna Inc. (MRNA)’s beta value is 1.60, and its average true range (ATR) is 9.99.

A comparison of Moderna Inc. (MRNA) with its peers suggests the former has fared considerably weaker in the market. MRNA showed an intraday change of -1.71% in today’s session so far, and over the past year, it shrunk by -53.66%%. In comparison, Johnson & Johnson (JNJ) has moved lower at -1.14% today and is down -0.91% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has fallen -0.70% today. The stock, however, is off 10.33% from where it was a year ago. The PE ratio stands at 5.71 for Moderna Inc., compared to 24.97 for Johnson & Johnson, and 9.61 for Pfizer Inc. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it lost -0.22%. Meanwhile, the Dow Jones Industrial Slipped by -0.04%.

Data on historical trading for Moderna Inc. (NASDAQ:MRNA) indicates that the trading volumes over the past 10 days have averaged 4.79 million and over the past 3 months, they’ve averaged 5.58 million. According to company’s latest data on outstanding shares, there are 402.00 million shares outstanding.

Nearly 5.30% of Moderna Inc.’s shares belong to company insiders and institutional investors own 64.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.29 million shares as on Jul 14, 2022, resulting in a short ratio of 2.87. According to the data, the short interest in Moderna Inc. (MRNA) stood at 4.09% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 14.76 million. The stock has fallen by -23.55% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MRNA stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]